Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

The agreement with Sanofi represents an essential step toward strengthening Iraq's pharmaceutical industry.

Investing.com -- Sanofi SA (EPA: SASY) announced Friday that its drug Sarclisa has received approval in the European Union for the treatment of transplant-eligible newly diagnosed multiple myeloma.

The European Commission has approved Sanofi’s Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple ...

Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Investing.com -- Sanofi SA (EPA: SASY) announced Friday that its drug Sarclisa has received approval in the European Union for the treatment of transplant-eligible newly diagnosed multiple myeloma ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The collaboration and licence option agreement will focus on identifying and ...

Sanofi’s entrenched vaccine and rare-disease franchises add to its competitive advantages, stemming from efficient scale in some rare-disease drugs and cost advantages in the vaccines division.